Dr. Bernicker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2030 Mountain View Ave
Ste 540
Longmont, CO 80501Phone+1 720-494-7110Fax+1 720-494-7111
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1994 - 1997
Baylor College of MedicineResidency, Internal Medicine, 1991 - 1993
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1990 - 1991- Baylor College of MedicineClass of 1990
Certifications & Licensure
CO State Medical License 2023 - 2025
TX State Medical License 1991 - 2024- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Most Compassionate Doctor American Registry
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
- Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy Start of enrollment: 2021 Oct 14
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 49 citationsHybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung CancerAlexa B. Schrock, Allison Welsh, Jon Chung, Dean Pavlick, Eric H. Bernicker
Journal of Thoracic Oncology. 2019-02-01 - 58 citationsCombined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancerSarah Croessmann, Luigi Formisano, Lisa N. Kinch, Paula I. Gonzalez-Ericsson, Dhivya R. Sudhan
Clinical Cancer Research. 2019-01-01 - 109 citationsUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of Ame...Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley
The Journal of Molecular Diagnostics. 2018-03-01
Authored Content
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase InhibitorsJanuary 2018
Press Mentions
Air Pollution – Second Leading Cause of Lung CancerSeptember 13th, 2021
A Delicate Dance: Immunocompromised Houstonians Turn to Virtual Boot-Scooting to Stay ConnectedApril 14th, 2020
Vaping Isn't Just Dangerous, It's LethalNovember 13th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
